Neuromyelitis Optica Spectrum Disorder Treatment and Management Strategies

Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune astrocytopathy marked by recurrent inflammation of the optic nerves and spinal cord. Acute management centres on rapid suppression of inflammation through high-dose corticosteroids and plasma exchange to limit irreversible tissue injury. Long-term strategies aim to prevent relapses that drive cumulative disability. Traditional immunosuppressants such as azathioprine and mycophenolate mofetil have been widely used, but newer targeted therapies—including complement inhibitors, B-cell depleting agents and interleukin-6 receptor antagonists—have demonstrated superior efficacy in randomised trials. Treatment choice is guided by antibody status, comorbidities and reproductive considerations, while ongoing monitoring of antibody titres, magnetic resonance imaging and disability scales informs adjustments. Emerging approaches seek to restore immune tolerance and personalise therapy through biomarkers of relapse risk. Globally, the shift towards mechanism-specific biologics promises improved outcomes, although access and long-term safety remain key challenges for clinicians and patients alike.

Research from Nature Portfolio

A longitudinal cohort study of patients with NMOSD has clarified that neurological deterioration accumulates almost exclusively during clinical attacks, with no evidence of secondary progressive decline in the absence of relapse. This finding underscores the critical need for relapse prevention as the primary determinant of long-term disability. In addition, a retrospective analysis of tacrolimus treatment in NMOSD demonstrated an approximate 85 percent reduction in annual relapse rate and significant improvement in disability scores, with favourable tolerability compared to conventional agents. These insights highlight the potential of alternative immunosuppressants beyond B-cell depletion to achieve robust control of disease activity.

Neuromyelitis Optica Spectrum Disorder Treatment and Management Strategies publication trend

The graph below shows the total number of articles in neuromyelitis optica spectrum disorder treatment and management strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Aquaporin-4 autoantibody: An IgG-class antibody that binds the water channel protein aquaporin-4 on astrocyte endfeet, serving as a key biomarker and pathogenic driver in NMOSD.

Complement inhibitor: A therapeutic agent that blocks activation of the complement cascade, thereby preventing immune-mediated damage to central nervous system tissues.

B-cell depleting agent: A monoclonal antibody that targets CD19 or CD20 surface antigens on B lymphocytes to reduce autoantibody production.

Interleukin-6 receptor antagonist: A biologic that blocks the receptor for interleukin-6, a cytokine implicated in NMOSD pathogenesis and inflammatory signalling.

Plasmapheresis: A procedure that removes circulating autoantibodies and inflammatory mediators from the plasma to rapidly control acute attacks.

Expanded Disability Status Scale (EDSS): A standardised scale ranging from 0 to 10 used to quantify neurological impairment and disability in demyelinating disorders.

References

1. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. Journal of Neurology (2023).
2. Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders. Scientific Reports (2020).
3. Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder. Scientific Reports (2017).
4. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. Journal of Neurology (2020).
5. Restoring immune tolerance in neuromyelitis optica. Neurology Neuroimmunology & Neuroinflammation (2016).